E
ThermoGenesis Holdings, Inc.
THMO
$0.00
$0.000.00%
E
Sell
3/14/2024Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to E+ from E on 3/14/2024 due to an increase in the volatility index and total return index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to E+ from E on 3/14/2024 due to an increase in the volatility index and total return index.
E
Sell
2/28/2024Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E from E+ on 2/28/2024 due to a decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.9104 to -$1.4439, and total revenue declined 3.48% from $2.27M to $2.19M.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E from E+ on 2/28/2024 due to a decline in the volatility index, solvency index and growth index. Earnings per share declined from -$0.9104 to -$1.4439, and total revenue declined 3.48% from $2.27M to $2.19M.
E
Sell
3/14/2023Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 03/14/2023.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
D
Sell
1/25/2023Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index and valuation index.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index and valuation index.
D
Sell
1/9/2023Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 1/9/2023 due to an increase in the volatility index and valuation index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 1/9/2023 due to an increase in the volatility index and valuation index.
D
Sell
12/23/2022Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 12/23/2022 due to a decline in the valuation index, growth index and volatility index. EBIT declined 39.74% from -$1.44M to -$2.02M, total revenue declined 30.17% from $3.03M to $2.12M, and operating cash flow declined 6.16% from -$942 to -$1M.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 12/23/2022 due to a decline in the valuation index, growth index and volatility index. EBIT declined 39.74% from -$1.44M to -$2.02M, total revenue declined 30.17% from $3.03M to $2.12M, and operating cash flow declined 6.16% from -$942 to -$1M.
D
Sell
5/16/2022Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 04/21/2022.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 1.05 to 2.68.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 1.05 to 2.68.
D
Sell
11/15/2021Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and valuation index. EBIT increased 64.79% from -$3.14M to -$1.11M, earnings per share increased from -$0.3811 to -$0.15, and total revenue increased 43.48% from $2.2M to $3.16M.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and valuation index. EBIT increased 64.79% from -$3.14M to -$1.11M, earnings per share increased from -$0.3811 to -$0.15, and total revenue increased 43.48% from $2.2M to $3.16M.
D
Sell
11/8/2021Downgrade
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index and efficiency index. Net income declined 88.11% from -$2.41M to -$4.54M, and total capital declined 9.14% from $18.49M to $16.8M.
ThermoGenesis Holdings, Inc. (THMO) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index and efficiency index. Net income declined 88.11% from -$2.41M to -$4.54M, and total capital declined 9.14% from $18.49M to $16.8M.
D
Sell
3/25/2020Upgraded
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 3/25/2020 due to a large increase in the total return index, efficiency index and volatility index.
ThermoGenesis Holdings, Inc. (THMO) was upgraded to D from D- on 3/25/2020 due to a large increase in the total return index, efficiency index and volatility index.
D
Sell
9/9/2019Upgraded
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 9/9/2019 due to an increase in the volatility index and total return index.
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 9/9/2019 due to an increase in the volatility index and total return index.
E
Sell
8/23/2019Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 8/23/2019 due to a decline in the volatility index and valuation index.
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 8/23/2019 due to a decline in the volatility index and valuation index.
D
Sell
6/19/2019Upgraded
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 6/19/2019 due to an increase in the valuation index and total return index.
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 6/19/2019 due to an increase in the valuation index and total return index.
E
Sell
6/4/2019Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 6/4/2019 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.14 to 0.64.
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 6/4/2019 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.14 to 0.64.
D
Sell
9/4/2018Upgraded
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 9/4/2018 due to an increase in the volatility index.
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 9/4/2018 due to an increase in the volatility index.
E
Sell
8/17/2018Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 8/17/2018 due to a noticeable decline in the solvency index, growth index and efficiency index. Net income declined 800.61% from -$2.96M to -$26.66M, earnings per share declined from -$0.2716 to -$1.7261, and debt to equity increased from 0.22 to 0.69.
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 8/17/2018 due to a noticeable decline in the solvency index, growth index and efficiency index. Net income declined 800.61% from -$2.96M to -$26.66M, earnings per share declined from -$0.2716 to -$1.7261, and debt to equity increased from 0.22 to 0.69.
D
Sell
5/23/2018Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to D- from D on 5/23/2018 due to a noticeable decline in the total return index, solvency index and growth index.
Cesca Therapeutics Inc. (KOOL) was downgraded to D- from D on 5/23/2018 due to a noticeable decline in the total return index, solvency index and growth index.
D
Sell
11/16/2017Upgraded
Cesca Therapeutics Inc. (KOOL) was upgraded to D from D- on 11/16/2017 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 31.02% from -$2.1M to -$1.45M.
Cesca Therapeutics Inc. (KOOL) was upgraded to D from D- on 11/16/2017 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 31.02% from -$2.1M to -$1.45M.
D
Sell
8/17/2016Upgraded
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 8/17/2016 due to an increase in the volatility index and total return index.
Cesca Therapeutics Inc. (KOOL) was upgraded to D- from E+ on 8/17/2016 due to an increase in the volatility index and total return index.
E
Sell
5/13/2016Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 5/13/2016 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.3016 to -$4.0035, EBIT declined 39.28% from -$1.97M to -$2.74M, and operating cash flow declined 20.88% from -$3.19M to -$3.86M.
Cesca Therapeutics Inc. (KOOL) was downgraded to E+ from D- on 5/13/2016 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.3016 to -$4.0035, EBIT declined 39.28% from -$1.97M to -$2.74M, and operating cash flow declined 20.88% from -$3.19M to -$3.86M.
D
Sell
3/11/2016Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.15 to 0.87.
Cesca Therapeutics Inc. (KOOL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.15 to 0.87.
D
Sell
5/7/2015Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to D from D+ on 5/7/2015 due to a large decline in the total return index, volatility index and efficiency index. Total capital declined 6.37% from $48.7M to $45.6M.
Cesca Therapeutics Inc. (KOOL) was downgraded to D from D+ on 5/7/2015 due to a large decline in the total return index, volatility index and efficiency index. Total capital declined 6.37% from $48.7M to $45.6M.
D
Sell
10/10/2014Downgrade
Cesca Therapeutics Inc. (KOOL) was downgraded to D+ from C- on 10/10/2014 due to a large decline in the growth index, volatility index and total return index. Total revenue declined 4.98% from $4.04M to $3.84M, and operating cash flow declined 1.3% from -$1.76M to -$1.74M.
Cesca Therapeutics Inc. (KOOL) was downgraded to D+ from C- on 10/10/2014 due to a large decline in the growth index, volatility index and total return index. Total revenue declined 4.98% from $4.04M to $3.84M, and operating cash flow declined 1.3% from -$1.76M to -$1.74M.
C
Hold
5/27/2014Upgraded
ThermoGenesis Corp. (KOOL) was upgraded to C- from D on 5/27/2014 due to a large increase in the volatility index, growth index and efficiency index. Total capital increased 328.09% from $9.63M to $41.23M, EBIT increased 99.28% from -$690 to -$1.38M, and net income increased 15.97% from -$1.6M to -$1.86M.
ThermoGenesis Corp. (KOOL) was upgraded to C- from D on 5/27/2014 due to a large increase in the volatility index, growth index and efficiency index. Total capital increased 328.09% from $9.63M to $41.23M, EBIT increased 99.28% from -$690 to -$1.38M, and net income increased 15.97% from -$1.6M to -$1.86M.
OTC PK
04/02/2025 10:41AM Eastern
Quotes delayed
